Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

2020 In Review: Highlights, Lowlights and Forgotten Milestones

Executive Summary

Our interactive timeline tracks the rush of activities that led to the authorization of the first coronavirus vaccines and includes other major non-COVID developments that provide a full picture of this extraordinary year.

You may also be interested in...



Drug Rejection Hearings Are Having A Moment At US FDA

With Intarcia's request, the rarely used mechanism could now produce two hearing this year, but outcomes of the few other times the process has been undertaken should not generate a lot of confidence for sponsors that this a path that they want to go down.

Improper Dose In Phase II Trials Can ‘Make Or Break’ Drug Program, FDA’s Stein Says

Director of the US FDA’s Office of New Drugs says there will be a greater focus on identifying the optimal dose before a drug candidate advances into Phase III trials, but the problem is not limited to oncology, the target of Project Optimus.

Some US FDA Advisory Committee Meetings Likely To Remain Virtual Post-Pandemic

Peter Stein says FDA will set criteria for holding a virtual meeting and will be seeking stakeholder feedback.

Topics

UsernamePublicRestriction

Register

PS143571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel